• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

iCAIR consortium initiates project to develop inhaled drugs for COVID-19

A consortium called Fraunhofer International Consortium for Anti-Infective Research (iCAIR) — composed of researchers from Fraunhofer ITEM, Griffith University, Hannover Medical School, and Twincore — has announced that it has initiated a project to develop inhaled drugs to treat COVID-19, starting with high-throughput screening for candidates by temporary consortium member Fraunhofer IME. The consortium will also explore the role of glycosylation in how SARS-CoV-2 affects patients.

The iCAIR consortium was already aiming to develop treatments for other respiratory viruses, including influenza, RSV, and other coronaviruses, as well as pathogens such as P. aeruginosa. According to a web page for the project, iCAIR is intended to facilitate development of anti-infectives by “bridging the gap from the discovery of new agents to their development by the pharmaceutical industry” and “The development platform established in the iCAIR project will be made available to external partners in addition to its use in proprietary projects.”

iCAIR consortium coordinator and Fraunhofer ITEM Director of Preclinical Pharmacology and Toxicology Armin Braun explained why the group intends to develop the leading candidates for inhaled delivery: “We will systematically investigate inhaled administration of the candidate drugs, as the coronavirus-2 primarily infects the lungs and airways. Administering therapeutics via the airways enables high local concentrations at the site of infection, reducing the required doses of active substance. In addition, systemic side effects can be minimized.”

Read the iCAIR press release.

Share

published on May 7, 2020

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews